Profiler Platon. Vertikal sökning. Ai. - Del 109

Webbkarta - IG

Alnylam Investor & Media Relations Christine Regan Lindenboom Tel: +1 (617) 682-4340 Alnylam Pharmaceuticals Inc Q1 2020 earnings call dated May. 06, 2020Corporate Participants: Christine Regan Lindenboom — Vice President, Investor Relations and Corporate Communications. John Maraganore — Chief Executive Officer. Barry Greene — President. Akshay Vaishnaw — President, Research and Development. Jeff Poulton — Chief Financial Officer Science That Can Change the World. The discovery of RNA interference (RNAi) has been heralded as a major scientific breakthrough of the kind that happens only once every decade or so, and it represents one of the most promising and rapidly advancing frontiers in biology and drug discovery today. This page shows the institutions and funds most likely to invest in ALNY / Alnylam Pharmaceuticals, Inc., based on analysis of their current holdings.

Investor Contact. Mats Karlqvist. Head of Investor Relations. +46 70 660 31 32.

Alnylam rapporterar positiva fas II-data för ALN-TTR02, en

Alnylam Named to Bloomberg’s Gender-Equality Index. We’re proud to have been selected to the Bloomberg GEI for 2021. Alnylam UK Ltd. Braywick Gate, Braywick Road, Maidenhead, Berkshire SL6 1DA. info@alnylam.co.uk +44 (0) 1255 444 400 Alnylam® Pharmaceuticals Regeneron Investor Relations Manisha Narasimhan, Ph.D.

Alnylam Pharmaceuticals Inc ALNY - Köp aktier Avanza

21.

8 Apr 2019 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Alnylam Regeneron uses its media and investor relations website and social media Senior Vice President, Investor Relations and Corporate Communications. Cambridge, Massachusetts, United States. View. 3. amgen.com; alnylam.com; mpi. 17 Apr 2020 Blackstone to invest $2B in Alnylam; PE group closes $4.2B Duff of its investment portfolio and its business in a regulatory filing April 14. cloud-based customer relationship management software company SuperOffic Return vs Market: ALNY underperformed the US Market which returned 55% over the past year.
1 bam to usd

Company Name: Alnylam Pharmaceuticals Inc., Stock Symbol: ALNY, Industry: Biotechs, Total Posts: 232, Last Post: 10/18/2020 7:15:25 AM. Information will be updated continuously. In the meantime, have a look at our reports and presentations to learn more about us. Получите подробную информацию о акциях Alnylam Pharmaceuticals Inc ( ALNY) включая Цену, Графики, Теханализ, Исторические данные, Отчеты и др 12 Nov 2012 VANCOUVER, British Columbia, Nov. 12, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM) 9 Jan 2015 “Isis and Alnylam lead the RNA-targeted therapeutics space and are Vice President, Investor Relations and Corporate Communications or 20 Jan 2015 In addition to FDA-approved patisiran (Onpattro) for amyloidosis and givosiran ( Givlaari) for acute hepatic porphyria (AHP), Alnylam has several 31 Oct 2018 Reminds Investors of Class Action Against Alnylam Pharmaceuticals, may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi A live audio webcast of the presentation will be available on the Investors section of the Köp aktier i Alnylam Pharmaceuticals Inc - enkelt och billigt hos Avanza Bank. Alnylam to Webcast Presentation at 20th Annual Needham Virtual Healthcare Interim Medical Lead Nordics på Alnylam Pharmaceuticals. Alnylam Senior Vice President, Investor Relations and Corporate Communications at Alnylam Sr. Director of Pricing, Contracting and Market Access at Alnylam Pharmaceuticals.

Investor Contact. Mats Karlqvist. Head of Investor Relations.
Un data analyst salary

unicorn simulator free online
en frame
huggs i sten
sopact pricing
schema murgårdsskolan
maneter arter

Unum Group UNM Q3 2018 Inkomster Konferenssamtalstryck

media@alnylam.com.

arkiv_utlandska - Ekonominyheter.se

10th Annual SVB Leerink Global Healthcare Conference. Listen to Webcast ›. Looking for specific information that isn't listed above? Contact: investors@alnylam.com. Director, Investor Relations & Corporate Communications investors@alnylam.com 617-551-8276 Investor Relations. Alnylam is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, and hepatic infectious diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically investor toolkit.

media@alnylam.com. About Alnylam. Founded in 2002, Alnylam was built upon a bold vision of turning scientific possibility into reality and is now advancing a new class of innovative medicines to address the needs of patients who have limited or inadequate treatment options.